BioTime, Inc. (ARCA:BTX) insider have most recently took part in a trading activity. On Aug 22, 2017 Broadwood Partners, L.p., Director, 10% Owner bought 10,000 shares having total worth of $26,000 at the price of $2.6 per share, following the transaction a total of 27,342,162 shares owned by Broadwood Partners, L.p.. Before this latest buy, Broadwood Partners, L.p. purchased BTX at 2 other times during the past twelve months, for a total investment of $64.2M at an average of $2.75 per share.
The stock has experienced a total of 6 insider trades in the past three months. These trades include 1 sell activities and 5 buy trades. Furthermore, over the past 12 months , the stock was traded 8 times by insiders. In 1 of these trades, the insider was a seller while an employee of the company was the buyer in 7 instances.
|Time Frame||Number of Insider Buy||Number of Insider Sell||Stock Price Change(%)|
Shares of BioTime, Inc. (ARCA:BTX) traded up 3.54% on Aug 22, 2017, hitting $2.63. 274,468 shares of the company’s stock traded hands. BioTime, Inc. has a 52 week low of $2.29 and a 52 week high of $3.97. The company’s market cap is $396 million.
BioTime, Inc. (ARCA:BTX) last announced its earnings results on Aug 2, 2017. The company reported -0.11 earnings per share (EPS) for the quarter. The company had revenue of $0 million for the quarter During the same quarter in the previous year, the company posted -0.11 earnings per share. The company’s revenue for the quarter was down 70% on a year-over-year basis.
|earnings per share||-0.11||-0.08||-0.05||-0.09||-0.11||-0.18||-0.12||-0.13||-0.14||-0.12|
BioTime, Inc. was incorporated in 1990 in the state of California. It is a biotechnology company engaged in two areas of biomedical research and product development. The Company has historically developed blood plasma volume expanders and related technology for use in surgery, emergency trauma treatment and other applications. Its focus is in the field of regenerative medicine; specifically human embryonic stem (“hES”) cell and induced pluripotent stem (“iPS”) cell technology. Regenerative medicine refers to therapies based on stem cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury. hES and iPS cells provide a means of manufacturing every cell type in the human body and therefore show considerable promise for the development of a number of new therapeutic products. The Company plans to develop stem cell products for research and therapeutic use through its subsidiaries. OncoCyte Corporation is developing products and technologies to diagnose and treat cancer. ES Cell International Pte., Ltd. (“ESI”), a Singapore private limited company, develops and sells hES products for research use. BioTime Asia, Limited a Hong Kong company, sells products for research use and may develop therapies to treat cancer, neurological, and orthopedic diseases. OrthoCyte Corporation is developing therapies to treat orthopedic disorders, diseases and injuries. ReCyte Therapeutics, Inc., formerly known as Embryome Sciences, Inc. is developing therapies to treat vascular and blood diseases and disorders. Cell Cure Neurosciences Ltd. is an Israel-based biotechnology company focused on developing stem cell-based therapies for retinal and neurological disorders, including the development of retinal pigment epithelial cells for the treatment of macular degeneration, and treatments for multiple sclerosis. LifeMap Sciences, Inc. markets GeneCards, the human gene database, and is developing an integrated database suite to complement GeneCards that will also include the LifeMap database of embryonic development, stem cell research and regenerative medicine, and MalaCards, the human disease database. Its products for use in stem cell research are being offered to researchers at universities and other institutions, at companies in the bioscience and biopharmaceutical industries, and at other companies that provide research products to companies in those industries. As of March 18, 2013, the company owned or controlled or licensed directly or through its subsidiaries 281 issued or allowed U.S. patents and also owned or controlled over 141 pending U.S. patent applications, including provisional patent applications, to protect its proprietary technologies. The Company also licensed 140 IP patents and applications from WARF. The Company and its subsidiaries face competition in both blood plasma expander business and regenerative medicine and stem cell business.
Latest posts by William White (see all)
- Insider Trading Review: FS Investment Corporation $FSIC - January 13, 2018
- Insider Trader Watch: ENERTOPIA CORP $ENRT - January 13, 2018
- Insider Trading in Focus: Swiss Helvetia Fund, Inc. (The) $SWZ - January 13, 2018